JP2023531311A5 - - Google Patents
Info
- Publication number
- JP2023531311A5 JP2023531311A5 JP2022580938A JP2022580938A JP2023531311A5 JP 2023531311 A5 JP2023531311 A5 JP 2023531311A5 JP 2022580938 A JP2022580938 A JP 2022580938A JP 2022580938 A JP2022580938 A JP 2022580938A JP 2023531311 A5 JP2023531311 A5 JP 2023531311A5
- Authority
- JP
- Japan
- Prior art keywords
- linear
- branched
- co2h
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025094025A JP7864902B2 (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045901P | 2020-06-30 | 2020-06-30 | |
| US63/045,901 | 2020-06-30 | ||
| US202063109095P | 2020-11-03 | 2020-11-03 | |
| US63/109,095 | 2020-11-03 | ||
| US17/364,047 | 2021-06-30 | ||
| PCT/CA2021/050907 WO2022000091A1 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
| US17/364,047 US11292765B2 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025094025A Division JP7864902B2 (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531311A JP2023531311A (ja) | 2023-07-21 |
| JP2023531311A5 true JP2023531311A5 (cg-RX-API-DMAC7.html) | 2024-07-09 |
| JP7702654B2 JP7702654B2 (ja) | 2025-07-04 |
Family
ID=79032374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580938A Active JP7702654B2 (ja) | 2020-06-30 | 2021-06-30 | トリプタミンプロドラッグ |
| JP2025094025A Active JP7864902B2 (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025094025A Active JP7864902B2 (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11292765B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4172145B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7702654B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102829078B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN119285527A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021302692A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181092A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4172145T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4172145T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL299506B2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT4172145T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016212A (cg-RX-API-DMAC7.html) |
| PT (1) | PT4172145T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022000091A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| AU2021215709A1 (en) | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| DK4172145T3 (da) * | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| WO2022040802A1 (en) * | 2020-08-26 | 2022-03-03 | Magicmed Industries Inc. | Glycosylated psilocybin derivatives and methods of using |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| JP2024520832A (ja) | 2021-06-08 | 2024-05-24 | エンセオジェニックス バイオサイエンシズ, インコーポレイテッド | セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤 |
| AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| KR20240065084A (ko) * | 2021-08-20 | 2024-05-14 | 테란 바이오사이언시스 인코포레이티드 | 사일로신의 전구약물 및 유도체 및 그의 용도 |
| WO2023086962A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| AU2022408191B2 (en) * | 2021-12-10 | 2025-05-15 | Caamtech, Inc. | Psilocybin derivatives |
| US20250051278A1 (en) * | 2021-12-14 | 2025-02-13 | Reunion Neuroscience, Inc. | Tryptamine prodrugs |
| CA3242479A1 (en) | 2021-12-27 | 2023-07-06 | Atai Therapeutics, Inc. | AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| US20250066299A1 (en) * | 2022-01-06 | 2025-02-27 | Terran Biosciences Inc. | Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20250186369A1 (en) * | 2022-03-07 | 2025-06-12 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder |
| AU2023235712A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| US12065404B2 (en) * | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493541A4 (en) * | 2022-03-18 | 2026-02-25 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBOXYLIC ACID AND METHODS OF USE |
| AU2022447256A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-carbonothioate-substituted tryptamine derivatives and methods of using |
| AU2023254841B2 (en) * | 2022-04-13 | 2025-10-23 | Caamtech, Inc. | Tryptamine derivatives |
| CN115521240B (zh) * | 2022-06-01 | 2024-05-28 | 杭州奥泰生物技术股份有限公司 | 一种二甲基色胺半抗原和人工抗原及其制备方法与应用 |
| AU2023313326A1 (en) * | 2022-07-27 | 2024-12-19 | Reconnect Labs Ag | Highly soluble formulations of harmine |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN116283885B (zh) * | 2022-12-01 | 2025-02-14 | 杭州奥泰生物技术股份有限公司 | 一种帕罗西汀半抗原和人工抗原及其制备方法与应用 |
| WO2024145719A1 (en) * | 2023-01-05 | 2024-07-11 | Reunion Neuroscience Inc. | Improved pharmacokinetics of tryptamine prodrugs |
| WO2024178051A2 (en) * | 2023-02-22 | 2024-08-29 | Caamtech, Inc. | Tryptamine derivatives |
| US12343319B2 (en) | 2023-05-01 | 2025-07-01 | Atai Therapeutics, Inc. | Compositions and methods for treatment of diseases and disorders |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025099725A1 (en) * | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2025250900A1 (en) * | 2024-05-30 | 2025-12-04 | Caamtech, Inc. | 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
| WO2026128398A1 (en) * | 2024-12-09 | 2026-06-18 | Reunion Neuroscience, Inc. | Treatment of adjustment disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| NL121067C (cg-RX-API-DMAC7.html) | 1958-09-12 | |||
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| WO1995006638A1 (en) * | 1993-09-01 | 1995-03-09 | Allelix Biopharmaceuticals Inc. | Tryptamine analogs with 5-ht1d selectivity |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2006047032A2 (en) | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| US8809261B2 (en) | 2008-10-31 | 2014-08-19 | Elsohly Laboratories, Incorporated | Compositions containing delta-9-THC-amino acid esters and process of preparation |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| DK4172145T3 (da) * | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
-
2021
- 2021-06-30 DK DK21832431.7T patent/DK4172145T3/da active
- 2021-06-30 CN CN202410898937.9A patent/CN119285527A/zh active Pending
- 2021-06-30 CA CA3181092A patent/CA3181092A1/en active Pending
- 2021-06-30 WO PCT/CA2021/050907 patent/WO2022000091A1/en not_active Ceased
- 2021-06-30 EP EP21832431.7A patent/EP4172145B1/en active Active
- 2021-06-30 AU AU2021302692A patent/AU2021302692A1/en active Pending
- 2021-06-30 FI FIEP21832431.7T patent/FI4172145T3/fi active
- 2021-06-30 KR KR1020237003292A patent/KR102829078B1/ko active Active
- 2021-06-30 KR KR1020257021837A patent/KR20250103811A/ko active Pending
- 2021-06-30 EP EP26177764.3A patent/EP4786000A2/en active Pending
- 2021-06-30 US US17/364,047 patent/US11292765B2/en active Active
- 2021-06-30 LT LTEPPCT/CA2021/050907T patent/LT4172145T/lt unknown
- 2021-06-30 CN CN202410898893.XA patent/CN119285526A/zh active Pending
- 2021-06-30 PT PT218324317T patent/PT4172145T/pt unknown
- 2021-06-30 JP JP2022580938A patent/JP7702654B2/ja active Active
- 2021-06-30 CN CN202180046999.1A patent/CN115867533B/zh active Active
- 2021-06-30 IL IL299506A patent/IL299506B2/en unknown
- 2021-06-30 MX MX2022016212A patent/MX2022016212A/es unknown
-
2022
- 2022-02-24 US US17/679,439 patent/US20220177427A1/en not_active Abandoned
-
2024
- 2024-09-30 US US18/902,773 patent/US20250129023A1/en active Pending
-
2025
- 2025-04-30 IL IL320601A patent/IL320601A/en unknown
- 2025-06-05 JP JP2025094025A patent/JP7864902B2/ja active Active
- 2025-08-22 US US19/308,120 patent/US20250382267A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292753B2 (en) | Compounds, compositions comprising same, and uses thereof in the treatment of psychiatric or neurological disorders | |
| JP2022545359A5 (cg-RX-API-DMAC7.html) | ||
| KR100523366B1 (ko) | 티에닐아졸일알콕시에탄아민, 이의 제조방법 및 이의 용도 | |
| KR20240019152A (ko) | 신규 전구약물 및 디메틸트립타민의 접합체 | |
| RU2005109913A (ru) | Азабициклоалкильные эфиры и их применение в качестве агонистов альфа7-nachr | |
| JP2024001048A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518046A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518050A5 (cg-RX-API-DMAC7.html) | ||
| CA2310141A1 (fr) | Utilisation de derives de benzhydryl sulfinyle pour traiter la somnolence d'origine medicamenteuse | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2024546138A5 (cg-RX-API-DMAC7.html) | ||
| JP2006500403A (ja) | キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用 | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| RU2011142154A (ru) | Производные фосфлокуназола, их синтез и применение в препаратах длительного действия | |
| JP2018534300A5 (cg-RX-API-DMAC7.html) | ||
| JP2024544698A5 (cg-RX-API-DMAC7.html) | ||
| JP2023525359A (ja) | Sarsの治療のための化合物 | |
| JP2026503618A5 (cg-RX-API-DMAC7.html) | ||
| JP2002529497A5 (cg-RX-API-DMAC7.html) | ||
| JP4094061B2 (ja) | シス置換アミノシクロプロパン誘導体 | |
| CA2474246A1 (en) | Alkylammonium salts of omeprazole and esomeprazole | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| JPH1036365A5 (cg-RX-API-DMAC7.html) | ||
| JPH06321939A (ja) | 縮合キノリル−ジヒドロピリジン、その製造法及び薬剤におけるその利用 | |
| JP2013525290A5 (cg-RX-API-DMAC7.html) |